Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

Maitreyee K. Jathal(University of California, Davis), P. Ghosh(The University of Texas Health Science Center at San Antonio)
British Journal of Cancer
June 17, 2019
Cited by 23


Related Papers